DCPH vs. PIRS, COLL, GMTX, ABCL, MIRM, LGND, SYRE, MNKD, PCRX, and XNCR
Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Pieris Pharmaceuticals (PIRS), Collegium Pharmaceutical (COLL), Gemini Therapeutics (GMTX), AbCellera Biologics (ABCL), Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND), Spyre Therapeutics (SYRE), MannKind (MNKD), Pacira BioSciences (PCRX), and Xencor (XNCR). These companies are all part of the "pharmaceutical preparations" industry.
Pieris Pharmaceuticals (NASDAQ:PIRS) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations.
40.1% of Pieris Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.0% of Deciphera Pharmaceuticals shares are owned by institutional investors. 8.9% of Pieris Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Deciphera Pharmaceuticals has a consensus target price of $23.00, indicating a potential upside of 60.06%. Given Pieris Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Deciphera Pharmaceuticals is more favorable than Pieris Pharmaceuticals.
Deciphera Pharmaceuticals received 42 more outperform votes than Pieris Pharmaceuticals when rated by MarketBeat users. Likewise, 65.71% of users gave Deciphera Pharmaceuticals an outperform vote while only 61.92% of users gave Pieris Pharmaceuticals an outperform vote.
Pieris Pharmaceuticals has higher earnings, but lower revenue than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Pieris Pharmaceuticals has a net margin of -57.33% compared to Pieris Pharmaceuticals' net margin of -119.33%. Pieris Pharmaceuticals' return on equity of -49.44% beat Deciphera Pharmaceuticals' return on equity.
In the previous week, Pieris Pharmaceuticals had 6 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 7 mentions for Pieris Pharmaceuticals and 1 mentions for Deciphera Pharmaceuticals. Pieris Pharmaceuticals' average media sentiment score of 1.00 beat Deciphera Pharmaceuticals' score of 0.01 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the news media.
Pieris Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.
Summary
Deciphera Pharmaceuticals beats Pieris Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Deciphera Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Deciphera Pharmaceuticals Competitors List
Related Companies and Tools
